Japan’s MHLW approves Biktarvy® for treatment of HIV-1 infection
Gilead Sciences announced that Japan’s MHLW has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily STR for treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor. March 26, 2019